Haodong Xu received his MD, MS, and PhD from Suzhou Medical College. He subsequently completed a residency in Anatomic and Clinical Pathology at Barnes-Jewish Hospital/Washington University School of Medicine, and a fellowship at the Armed Forces Institute of Pathology. He is currently Professor of Head and Neck and Cardiothoracic Pathology at the David Geffen School of Medicine at UCLA. In addition, his interests also include molecular mechanisms of lung, head and neck tumors, and fibrosing interstitial pneumonia, and his basic research is focused on delineating the regulation mechanisms of voltage-gated cardiac ion channels.

Autopsy, Cardiopulmonary, and Head & Neck

Dr. Luo been studying molecular pathology related to human malignancies in the last 27 years. Currently, he is a Professor of Pathology and Director of High Throughput Genome Center at University of Pittsburgh. In the last 15 years, Dr. Luo has been largely focusing on genetic and molecular mechanism of human prostate and hepatocellular carcinomas. In this period, his group has identified and characterized several genes that are related to prostate cancer and hepatocellular carcinoma, including SAPC, myopodin, CSR1, GPx3, ITGA7, MCM7, MT1h and GPC3. He has characterized several signaling pathways that play critical role in prostate cancer development, including Myopodin-ILK-MCM7 inhibitory signaling, myopodin-zyxin motility inhibition pathway, CSR1-CPSF3 and CSR1-XIAP apoptotic pathways, MT1h-EHMT1 egigenomic signaling, ITGA7-HtrA2 tumor suppression pathway, GPx3-PIG3 cell death pathway, and AR-MCM7 oncogenic pathway. He proposed prostate cancer field effect in 2002. He is one of the pioneers in utilizing high throughput gene expression and genome analyses to analyze field effects in prostate cancer and liver cancer. He is also the first in using methylation array and whole genome methylation sequencing to analyze prostate cancer. Recently, Dr. Luo’s group found that patterns of copy number variants of certain specific genome loci are predictive of prostate cancer clinical outcomes, regardless tissue origin. His discovery of several novel fusion transcripts and their association with aggressive prostate cancer has brought significant new insight into the field of prostate cancer research. Overall, these discoveries advance our understanding on how cancer develops and behaves, and lay down the foundation for better future diagnosis and treatment of human malignancies.

Prostate cancer Research

K. H. Ramesh did his PhD, in Human Cancer Cytogenetics from Bangalore University, India. He trained under the guidance of world renowned geneticist Avery Sandberg, MD., at Roswell Park Cancer Institute, Buffalo, USA. He is Board Certified in Clinical Cytogenetics; currently a Diplomate of the American Board of Medical Genetics and Genomics, and Fellow of the American College of Medical Genetics and Genomics. At present he is the Director of Cancer CytoGenomics and Associate Professor of Pathology at Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, USA. He has over 25 years of experience in Human Cancer Genetics

Pathology, Human Cancer Genetics

Gabriela Oprea-Ilies has a medical degree from The Institute of Medicine and Pharmacy, Bucharest, Romania. She completed pathology residency at the University of Minnesota, Twin Cities and Cytology fellowship at Emory University, Atlanta, GA. She studied breast cancer with Dr. Schnitt, Collins and Mallory, in Boston. Currently she is a pathologist, Assistant Professor and Principal Investigator of the breast tissue bank at Emory University, Director of the Immunolab at Grady Memorial Hospital and Adjunct Professor at Georgia State University. She has published in reputed journals, has been reviewing papers and serving in the editorial board member of repute.

Pathology

Wenqing Cao, MD is a gastrointestinal pathologist and assistant professor at University of Rochester Medical Center. She received her Medical Degree from Tongji Medical University, China. She completed Anatomic and Clinical Pathology residency at Northwester University and Gastrointestinal Pathology fellowship at the Mount Sinai Medical Center. Since 1998, Dr. Cao has done extensive basic and clinical translational research in GI malignancies. He has published more than 20 papers in reputed journals and has been serving as an editorial board member.

GI malignancies

C Cameron Yin has received her MD from Beijing Medical University and her PhD from the University of Wisconsin-Madison. She is currently an associate professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center and UT Graduate School of Biomedical Sciences. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, Hematology and Molecular Genetic Pathology. In addition to clinical responsibilities on the Leukemia, Lymphoma and Molecular Diagnostic Laboratory services, Dr. Yin has been actively participating in multiple research projects in leukemia and lymphoma, which has led to over 100 research papers and over 20 book chapters. She serves as members of editorial boards for over 20 journals and ad hoc reviewers for over 30 journals. Her major research interests include molecular genetic aberrations in leukemia and lymphoma, development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms, mechanisms of resistance to tyrosine kinase inhibitors in patients with chronic myelogenous leukemia, as well as the role of immunoglobulin gene rearrangement in acute myeloid leukemia.

Molecular genetic aberrations in leukemia and lymphoma Development of molecular methodologies for the diagnosis, prognosis and minimal residual disease monitoring of hematopoietic neoplasms Mechanisms of imatinib resistance in patients with chronic myelogenous leukemia Immunoglobulin gene rearrangement in acute myeloid leukemia

Dr. Shaoying Li has received her MD from Beijing Medical University (Current name: Peking University Health Science Center). She is currently an assistant professor in the Department of Hematopathology at the University of Texas MD Anderson Cancer Center. She is board certified by the American Board of Pathology in Anatomic Pathology, Clinical Pathology, and Hematology. In addition to clinical responsibilities on Lymphoma, leukemia, and flow cytometry services, Dr. Li has been actively participating in multiple research projects in lymphoma and leukemia, which has led to over 30 research papers and multiple book chapters. She also serves as members of editorial boards and ad hoc reviewers for multiple journals. Her major research interests include molecular cytogenetic risk stratification of DLBCL with a focus on “double hit” lymphoma and MYC/BCL2 double expresser lymphoma, clinicopathologic and molecular study of mantle cell lymphoma, and molecular genetic aberrations in lymphoma and leukemia.

Molecular cytogenetic risk stratification of DLBCL Double hit lymphoma and MYC/BCL2 double expresser lymphoma Clinicopathologic and molecular study of mantle cell lymphoma Molecular genetic aberrations in lymphoma and leukemia